Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARNEST Rifabutin PK Substudy
NCT01663168Phase 2Unknown
- Start
- Dec 2011
- Primary completion
- Jan 2014
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifabutin in Tuberculosis (TB). Primary endpoint: Grade 3/4 adverse events at 24 weeks. Status: unknown.
02
Drugs
rifabutin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01663168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663168.